Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis

Published:2018-02-05 Issue:3 Volume:26 Page:513-521
ISSN:1930-7381
Container-title:Obesity
language:en
Short-container-title:Obesity

Author:

Onakpoya Igho J.¹^ORCID,Collins Dylan R.J.¹,Bobrovitz Niklas J.H.¹,Aronson Jeffrey K.¹,Heneghan Carl J.¹

Affiliation:

1. Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter; University of Oxford; Oxford UK

Funder

Clarendon Fund

DPhil program in Primary Health Care at the University of Oxford

National Institute for Health Research School for Primary Care Research (NIHR-SPCR)

Publisher

Wiley

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)

Reference49 articles.

1. Health effects of overweight and obesity in 195 countries over 25 years;The GBD 2015 Obesity Collaborators;N Engl J Med,2017

2. Update on treatment strategies for obesity;Wyatt;J Clin Endocrinol Metab,2013

3. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review;Onakpoya;BMC Med,2016

4. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012;Downing;JAMA,2014

5. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials;Higgins;BMJ,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Médicaments anti-obésité : leçons des échecs pour l’avenir;Médecine des Maladies Métaboliques;2021-12

2. Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses;Obesity Reviews;2021-04-12

3. Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports;British Journal of Clinical Pharmacology;2020-02-04

4. Lorcaserin in obesity: minimal benefits and ill-defined harms;BMJ Evidence-Based Medicine;2019-01-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3